AIS Healthcare Recognized with URAC Leader in Performance Measurement Award
To be recognized with the Pioneer in Performance Measurement Award, an organization is required to make key contributions to advance performance measurements and participate in activities that go beyond the mandatory reporting requirements, such as submission of exploratory measures, all with the purpose of helping improve the health and well-being of the populations being served.
URAC is one of the nation's leading independent health care accreditation organizations, with certification programs that set the highest standards in quality and safety.
'We are honored to have been named a 2024 Pioneer by URAC,' said Simon Castellanos, AIS Healthcare CEO. 'This recognition, for the second year in a row, is a testament to the dedication of our entire company to put patient safety first. I could not be prouder of this team and their unwavering commitment to ensuring quality, sterility, and excellence across all our pharmacy operations.
As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. This accomplishment underscores the company's commitment to going beyond what's expected to advance quality care and improve the lives of patients.
AIS Healthcare is also dually accredited by URAC and the Accreditation Commission for Health Care (ACHC), further setting it apart from other compounding pharmacies and infusion services providers.
Learn more at aiscaregroup.com
About AIS Healthcare
Advancing quality. Improving lives.
As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.
Learn more at aiscaregroup.com
About URAC
Founded in 1990, URAC is the independent leader in promoting healthcare quality through leadership, accreditation, measurement and innovation. URAC is a nonprofit organization using evidence-based measures and developing standards through inclusive engagement with a range of stakeholders committed to improving the quality of healthcare. Our portfolio of accreditation and certification programs span the healthcare industry, addressing healthcare management, healthcare operations, health plans, pharmacies, telehealth providers, physician practices and more. URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Deadline Soon: 3D Systems Corporation (DDD) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired 3D Systems Corporation ('3D Systems' or the 'Company') (NYSE: DDD) securities between August 13, 2024 and May 12, 2025, inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO LOST MONEY ON 3D SYSTEMS CORPORATION (DDD), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On March 26, 2025, 3D Systems released its fourth quarter and full year 2024 financial results, missing consensus estimates in non-GAAP earnings-per-share and sales revenue, citing 'lowers hardware systems sales due to macroeconomic factors that are negatively impacting demand.' The Company also reported a '$9 million revenue reduction in Q4 driven by a change in accounting estimates for [the Company's] Regenerative Medicine program." The Company disclosed that "[t]his change in estimate [was] related to the now anticipated use of pre-clinical human decedent testing . . . which led to refinement of the milestone technical criteria." On this news, 3D Systems' stock price fell $0.57, or 21%, to close at $2.15 per share on March 27, 2025, thereby injuring investors. Then, on May 12, 2025, after market hours, 3D Systems released its first quarter 2025 financial results, missing consensus estimates due, in part, to a decline in material sales, mostly due to inventory management issues in the dental portion of its Healthcare Solutions segment. The Company further disclosed that it was withdrawing its full-year 2025 outlook, citing prolonged softness in customer capital spending and macroeconomic uncertainty. On this news, 3D Systems' stock price fell $0.68, or 26.6%, to close at $1.87 per share on May 13, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (2) the updated milestone criteria in the United Partnership would negatively impact the Company's Regenerative Medicine Program revenue; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired 3D Systems securities between August 13, 2024 and May 12, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is August 12, 2025. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us: Frank R. Cruz The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Email us at: info@ Call us at: 310-914-5007 Visit our website at Follow us for updates on Twitter: If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
19 minutes ago
- Business Wire
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming August 11, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT) securities between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On May 27, 2025, Rocket disclosed that the FDA had placed a clinical hold on the Phase 2 pivotal trial of its Danon disease treatment, RP-A501, after at least one patient died following a substantive amendment to the protocol that the Company had not disclosed until after the Serious Adverse Event ('SAE') occurred. On this news, Rocket's stock price fell $3.94, or 62.8%, to close at $2.33 per share on May 27, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Rocket knew SAEs, including death of participants enrolled in the study, were a risk; (2) Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Rocket securities between September 17, 2024 and May 26, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is August 11, 2025. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us: Frank R. Cruz The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Email us at: info@ Call us at: 310-914-5007 Visit our website at Follow us for updates on Twitter: If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
19 minutes ago
- Business Wire
Deadline Approaching: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Novo Nordisk A/S ('Novo Nordisk' or the 'Company') (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 29, 2025, Novo Nordisk cut its previously issued fiscal year 2025 guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s. On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Novo Nordisk repeatedly ignored and minimized the significance of the personalization exception for GLP-1 compounding, greatly overestimated its ability to capture patients coming off of compounded treatments, and was ultimately ill equipped to capitalize upon the purported significant unmet patient population; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Novo Nordisk securities during the Class Period, you may move the Court no later than September 30, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
